Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine. MDX consists of a single bi-layer oral tablet, which includes both a rapid onset release metadoxine formulation and a slow release metadoxine formulation together providing the desired dual release profile. The new extended-release formulation prolongs the human plasma levels of metadoxine for up to 12 hours, which results in enhanced efficacy benefits. ADAIR is an oral, semi-solid, liquid-filled, hard gelatin capsule of an abuse-deterrent IR formulation of dextroamphetamine sulfate, which is manufactured as 10 mg capsules.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ADHD
- CUSIP: N/A
- Web: www.alcobra-pharma.com
- Market Cap: $30.87 million
- Outstanding Shares: 27,562,000
- 50 Day Moving Avg: $1.05
- 200 Day Moving Avg: $1.12
- 52 Week Range: $0.83 - $4.79
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.29
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.48 per share
- Price / Book: 0.76
- EBIDTA: ($21,410,000.00)
- Return on Equity: -45.34%
- Return on Assets: -42.69%
- Current Ratio: 25.53%
- Quick Ratio: 25.53%
- Average Volume: 80,458 shs.
- Beta: 1.5
- Short Ratio: 13.65
Frequently Asked Questions for Alcobra (NASDAQ:ADHD)
What is Alcobra's stock symbol?
Alcobra trades on the NASDAQ under the ticker symbol "ADHD."
How were Alcobra's earnings last quarter?
Alcobra Ltd. (NASDAQ:ADHD) issued its quarterly earnings results on Friday, August, 11th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. View Alcobra's Earnings History.
When will Alcobra make its next earnings announcement?
Where is Alcobra's stock going? Where will Alcobra's stock price be in 2017?
8 brokers have issued 12 month price targets for Alcobra's shares. Their predictions range from $1.00 to $4.00. On average, they expect Alcobra's stock price to reach $2.02 in the next twelve months. View Analyst Ratings for Alcobra.
What are analysts saying about Alcobra stock?
Here are some recent quotes from research analysts about Alcobra stock:
- 1. According to Zacks Investment Research, "Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel. " (8/1/2017)
- 2. Cantor Fitzgerald analysts commented, "Development of new drugs carries a high failure rate, either because the drug in question fails to show efficacy or significant safety issues arise during the clinical trial process. In addition, regulatory authorities such as the Food & Drug Administration (FDA) may delay the approval process or reject Alcobra’s clinical findings." (4/13/2017)
Who are some of Alcobra's key competitors?
Some companies that are related to Alcobra include TRACON Pharmaceuticals (TCON), Flex Pharma (FLKS), Endocyte (ECYT), Microbot Medical (MBOT), vTv Therapeutics (VTVT), Dipexium Pharmaceuticals (PLXP), KemPharm (KMPH), Leap Therapeutics (LPTX), Xenon Pharmaceuticals (XENE), OptiBiotix Health PLC (OPTI), Capricor Therapeutics (CAPR), Aldeyra Therapeutics (ALDX), Avacta Group Plc (AVCT), Proteostasis Therapeutics (PTI), Actinium Pharmaceuticals (ATNM), pSivida Corp. (PSDV), Inotek Pharmaceuticals Corporation (ITEK) and Ampio Pharmaceuticals (AMPE).
Who are Alcobra's key executives?
Alcobra's management team includes the folowing people:
- Yaron Daniely, Chairman of the Board
- David C. Baker, Interim Chief Executive Officer and Chief Commercial Officer
- Tomer Berkovitz, Chief Financial Officer
- Hagit Marchaim Ph.D., Senior Vice President - Regulatory Affairs
- Hanna Ron, Senior Vice President of Chemistry, Manufacturing and Control
- Oded Edri, Vice President - Finance
- Johanna Schumann, Vice President - Preclinical Development
- Jonathan Rubin M.D., Chief Medical Officer
- Daniel E. Geffken CPA, Director
- Aharon Schwartz, Director
Who owns Alcobra stock?
Alcobra's stock is owned by a number of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (16.25%), Royce & Associates LP (2.70%), Kingdon Capital Management L.L.C. (1.09%), Palo Alto Investors LLC (0.99%) and Worth Venture Partners LLC (0.99%). View Institutional Ownership Trends for Alcobra.
Who sold Alcobra stock? Who is selling Alcobra stock?
Who bought Alcobra stock? Who is buying Alcobra stock?
How do I buy Alcobra stock?
Shares of Alcobra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alcobra's stock price today?
MarketBeat Community Rating for Alcobra (NASDAQ ADHD)MarketBeat's community ratings are surveys of what our community members think about Alcobra and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Alcobra stock can currently be purchased for approximately $1.12.
Consensus Ratings for Alcobra (NASDAQ:ADHD) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 6 Hold Ratings, 1 Buy Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||$2.02 (80.48% upside)|
Analysts' Ratings History for Alcobra (NASDAQ:ADHD)
(Data available from 9/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|6/12/2017||Jefferies Group LLC||Reiterated Rating||Hold||$1.25||Low|
|5/31/2017||Roth Capital||Set Price Target||Buy||$4.00||High|
|4/13/2017||Cantor Fitzgerald||Reiterated Rating||Hold||$1.00||Low|
|1/17/2017||Stifel Nicolaus||Set Price Target||Hold||$2.00||N/A|
|1/17/2017||Oppenheimer Holdings, Inc.||Reiterated Rating||Hold||N/A|
|1/17/2017||Piper Jaffray Companies||Set Price Target||Hold||$3.00 -> $2.00||N/A|
|11/2/2016||WBB Securities||Upgrade||Sell -> Hold||$4.00 -> $1.90||N/A|
|10/28/2016||Barclays PLC||Downgrade||Equal Weight -> Underweight||$3.00 -> $2.00||N/A|
|9/1/2016||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Buy||N/A|
|6/7/2016||Canaccord Genuity||Initiated Coverage||Buy||N/A|
Earnings History for Alcobra (NASDAQ:ADHD)Earnings History by Quarter for Alcobra (NASDAQ ADHD)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/15/2016||Q316||($0.27)||($0.28)||$4.30 million||$7.90 million||View||N/A|
Earnings Estimates for Alcobra (NASDAQ:ADHD)
2017 EPS Consensus Estimate: ($0.71)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Alcobra (NASDAQ:ADHD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Alcobra (NASDAQ:ADHD)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Alcobra (NASDAQ:ADHD)
Latest Headlines for Alcobra (NASDAQ:ADHD)
Alcobra (ADHD) Chart for Friday, September, 22, 2017